Total Funding
19
46
Total FundingSeries A raised
Growth Score
-6 pts
Heat Score
-1 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
72180
Recombinetics targets biomedical and regenerative medicine, opening vast new opportunities to improve and extend human life.
- Perry Hackett: Co-Founder and Board MemberPast Role: Discovery Genomics, Co-Founder, Chief Science Officer, and Chairman of the Board
Ohad Gafni: Director of Stem Cells TechnologiesPast Role: University of Minnesota, Assistant Professor
About the Company
Recombinetics is a developer of gene editing technologies to improve human health through advanced disease models and regenerative medicine. Its gene-editing technologies manipulate deoxyribonucleic acid (DNA) samples to add and activate genes to solve problems and also offer gene repair and gene editing tools that enable biomedical research,
livestock productivity, animal agriculture, and livestock vertical markets to modify animal genomes accurately and efficiently.
